CSIMarket
 


Abvc Biopharma Inc   (ABVC)
Other Ticker:  
 

Abvc Biopharma Inc 's Working Capital Ratio

ABVC's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Abvc Biopharma Inc 's Current Assets grew by 17.13 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Abvc Biopharma Inc 's Working Capital Ratio to 0.46, Working Capital Ratio remained below Abvc Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 496 other companies have achieved higher Working Capital Ratio than Abvc Biopharma Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 4359, from total ranking in the second quarter 2023 at 4677.

Explain Working Capital Ratio
How much in Current Assets ABVC´s has?
What is the value of ABVC´s Current Liabilities?


ABVC Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 37.72 % 58.34 % 38.52 % 57.61 % 13.24 %
Y / Y Current Assets Change -14.11 % -78.25 % -56.43 % -68.96 % -59.17 %
Working Capital Ratio MRQ 0.46 0.37 0.69 0.51 0.75
ABVC's Total Ranking # 4359 # 4677 # 4544 # 5312 # 5208
Seq. Current Liabilities Change -7.1 % 13.75 % -12.79 % 49.44 % 6.81 %
Seq. Current Assets Change 17.13 % -38.83 % 16.5 % 2.9 % -70.34 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 497
Healthcare Sector # 1011
Overall Market # 4351


Working Capital Ratio Statistics
High Average Low
153.15 7.19 0
(Mar 31 2016)   (Sep 30 2013)




Financial Statements
Abvc Biopharma Inc 's Current Liabilities $ 5 Millions Visit ABVC's Balance sheet
Abvc Biopharma Inc 's Current Assets $ 2 Millions Visit ABVC's Balance sheet
Source of ABVC's Sales Visit ABVC's Sales by Geography


Cumulative Abvc Biopharma Inc 's Working Capital Ratio

ABVC's Working Capital Ratio for the trailling 12 Months

ABVC Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 37.72 % 58.34 % 38.52 % 57.61 % 13.24 %
Y / Y Current Assets TTM Growth -14.11 % -78.25 % -56.43 % -68.96 % -59.17 %
Working Capital Ratio TTM 0.5 0.56 1.04 1.39 2.03
Total Ranking TTM # 3433 # 3461 # 3620 # 4016 # 1807
Seq. Current Liabilities TTM Growth -7.1 % 13.75 % -12.79 % 49.44 % 6.81 %
Seq. Current Assets TTM Growth 17.13 % -38.83 % 16.5 % 2.9 % -70.34 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the III Quarter 2023 to $5.36 millions, cumulative Working Capital Ratio decreased to 0.5 below the Abvc Biopharma Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 452 other companies have achieved higher Working Capital Ratio than Abvc Biopharma Inc . While Working Capital Ratio overall ranking has improved so far to 3433, from total ranking during the twelve months ending second quarter 2023 at 3461.

Explain Working Capital Ratio
How much in Current Assets ABVC´s has?
What is the value of ABVC´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 453
Healthcare Sector # 938
Within the Market # 3433


trailing twelve months Working Capital Ratio Statistics
High Average Low
11.52 1.99 0.48
(Mar 31 2018)   (Jun 30 2021)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Cellectar Biosciences inc   1.23 $ 20.110  Millions$ 16.415  Millions
Therapeuticsmd Inc   1.20 $ 17.441  Millions$ 14.512  Millions
Unicycive Therapeutics Inc   1.20 $ 18.569  Millions$ 15.456  Millions
Bausch Health Companies Inc   1.20 $ 5,048.000  Millions$ 4,224.000  Millions
Aeon Biopharma inc   1.19 $ 16.911  Millions$ 14.177  Millions
Durect Corp  1.19 $ 43.780  Millions$ 36.752  Millions
Bristol myers Squibb Company  1.18 $ 27,632.000  Millions$ 23,462.000  Millions
Veru Inc   1.16 $ 23.506  Millions$ 20.279  Millions
Collegium Pharmaceutical Inc   1.16 $ 537.086  Millions$ 464.612  Millions
Novartis Ag  1.16 $ 30,481.000  Millions$ 26,390.000  Millions
Skye Bioscience Inc   1.11 $ 15.286  Millions$ 13.719  Millions
Ibio inc   1.11 $ 23.022  Millions$ 20.708  Millions
Ptc Therapeutics inc   1.10 $ 540.362  Millions$ 492.118  Millions
Emergent Biosolutions Inc   1.09 $ 720.800  Millions$ 664.000  Millions
Aytu Biopharma Inc   1.08 $ 70.599  Millions$ 65.463  Millions
Protokinetix Incorporated  1.07 $ 0.013  Millions$ 0.013  Millions
Molecular Templates inc   1.06 $ 22.700  Millions$ 21.512  Millions
Nascent Biotech Inc  1.05 $ 1.043  Millions$ 0.995  Millions
Kineta Inc   1.03 $ 7.843  Millions$ 7.615  Millions
Fortress Biotech Inc   1.00 $ 97.826  Millions$ 97.351  Millions
Teva Pharmaceutical Industries Limited  1.00 $ 11,425.000  Millions$ 11,394.000  Millions
Corbus Pharmaceuticals Holdings Inc   0.99 $ 31.206  Millions$ 31.542  Millions
Paxmedica Inc   0.99 $ 3.234  Millions$ 3.271  Millions
Nighthawk Biosciences inc   0.99 $ 24.180  Millions$ 24.488  Millions
Vtv Therapeutics Inc   0.99 $ 10.125  Millions$ 10.275  Millions
Journey Medical Corporation  0.98 $ 44.686  Millions$ 45.413  Millions
Reviva Pharmaceuticals Holdings Inc   0.98 $ 5.387  Millions$ 5.501  Millions
Aravive Inc   0.98 $ 9.562  Millions$ 9.777  Millions
Mustang Bio inc   0.96 $ 13.588  Millions$ 14.166  Millions
Abbvie inc   0.96 $ 33,224.000  Millions$ 34,773.000  Millions

Date modified: 2023-11-17T21:10:02+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com